Conference News

EADV 2022 Data Show Lebrikizumab Atopic Dermatitis Effects Maintained Lebrikizumab shows good long-term efficacy and reasonable safety in patients with moderate to severe atopic dermatitis according to the 52-week results from the phase 3 ADvocate1 and ADvocate2 trials.
News, September 30, 2022
EASD 2022 Strong Link Found Between Enterovirus and Type 1 Diabetes Relationship is particularly high within 1 month of type 1 diabetes onset, suggesting potential preventive role for vaccination or antivirals.
News, September 30, 2022
Hormones' Impact Described in Transgender Rheumatology Patients Gender-affirming hormone therapy does not need to be a strict contraindication in transgender patients with rheumatic disease, an author of a new case series and systematic review said.
News, September 30, 2022
EASD 2022 Improve Diagnosis of Type of Heart Failure Common in Diabetes Heart failure with preserved ejection fraction is common in people with type 2 diabetes but is often hard to recognize. Treatments newly proven to be effective make diagnosis an imperative.
News, September 30, 2022
Sex Differences Seen in Inflammatory Arthritis Healthcare Use Women’s higher risk of conditions such as osteoarthritis and pain and fatigue may help to explain why overall healthcare resource use was higher in female patients with inflammatory arthritis.
News, September 30, 2022
ESMO 2022 I Am Not Fine: The Heavy Toll Cancer Takes Everyone — patients, caregivers, nurses, doctors — is affected by the burden of cancer, no matter the side of the fence they're on.
News, September 30, 2022
EADV 2022 BREEZE-AD-PEDS: First Data for Baricitinib in Childhood Eczema The first pediatric trial of baricitinib for childhood eczema suggests that symptoms improve, and the safety profile is similar to that seen in adults.
News, September 30, 2022
EASD 2022 Once-Weekly Insulin Promising in Phase 3 Trial in Type 2 Diabetes Novo Nordisk's insulin icodec was superior in lowering A1c compared with daily degludec without increasing the risk for moderate or severe hypoglycemia in adults with type 2 diabetes already taking basal insulin.
News, September 29, 2022
EADV 2022 Alopecia Areata: Positive Data Reported for Two JAK Inhibitors JAK inhibitor therapy is hailed as "transformative" for patients with alopecia areata by one of the investigators reporting study results.
News, September 29, 2022
Severe COVID-19–Related Outcomes Found Worse in Men With RA A retrospective electronic health record study of patients with rheumatoid arthritis and COVID-19 showed that men had more baseline comorbidities and increased risk of COVID-19 outcomes than females.
News, September 29, 2022
EADV 2022 Study Identifies Skin Biomarkers That Predict Newborn Eczema Risk During the first 2 months of life, changes in skin biomarkers were predictive of whether children would develop atopic dermatitis up to 2 years later.
News, September 28, 2022
EASD 2022 Will Insulin Treatment Disappear in Type 2 Diabetes? At EASD, two experts debate the future of insulin therapy for type 2 diabetes.
News, September 28, 2022
ESMO 2022 Neoadjuvant Immunotherapy Shows Promise for Resectable CSCC Some patients develop more advanced cancer that requires surgery, often on exposed surfaces like the scalp, face, or neck.
News, September 27, 2022
EASD 2022 Does COVID-19 Cause Type 1 Diabetes in Kids? Time Will Tell Norwegian study finds association of SARS-CoV-2 with type 1 diabetes if diagnosed over 30 days after infection, while Scottish study finds no such link. More data are needed.
News, September 27, 2022
EASD 2022 Unsure on the Best T2D Drug Choice? Let Patients Decide The concept underwent successful testing in a recent trial of 457 patients with type 2 diabetes already on treatment with metformin or metformin plus a sulfonylurea but needed further glycemic control.
News, September 26, 2022
EASD 2022 Emphasis on Weight Loss in New Type 2 Diabetes Guidance No major changes but several shifts in emphasis since the last update in 2019, including weight loss as a co-primary goal of management.
News, September 26, 2022
MDS 2022 High Prevalence of COVID-Related Hospitalization, Mortality in PD Not only has the prevalence of COVID-19 been high among patients with Parkinson's disease, but there is also a high rate of related hospitalizations and mortality, a new meta-analysis shows.
News, September 26, 2022
ESMO 2022 What Is Known About Sexual Dysfunction After Breast Cancer? Among women with breast cancer, sexual dysfunction often predates the cancer diagnosis and worsens in the following 2 years, according to an analysis of prospective data.
News, September 26, 2022
TCT 2022 Cre8 EVO Stent Loses Sweet Spot in Diabetes at 2 Years: SUGAR Outcomes once deemed "almost too good to be true" disappeared with longer follow-up in an all-comer population of patients with diabetes undergoing revascularization.
News, September 23, 2022
MDS 2022 Trans-auricular VNS 'Very Clever' for Parkinson's Disease Novel, noninvasive trans-auricular vagus nerve stimulation is feasible, well tolerated, and may improve motor function in patients with Parkinson's Disease, new research suggests.
News, September 23, 2022

No Results